Mechanism of Action of Tranexamic Acid in Trauma-Related Bleeding

Pharmacodynamic Effects

• An antifibrinolytic concentration of approximately 10 μg/mL is required to effectively inhibit fibrinolysis, which is clinically relevant for patients with abnormal bleeding due to local or systemic hyperfibrinolysis 2, 3

Clinical Relevance of the Mechanism

• This antifibrinolytic mechanism makes TXA particularly effective in trauma-related bleeding, where accelerated fibrinolysis contributes to ongoing hemorrhage 1, 2
• TXA's mechanism requires direct contact with the bleeding site or adequate systemic concentrations—this is why timing of administration matters significantly, with efficacy declining after 3 hours post-injury when fibrinolysis is most active 1

Important Mechanistic Cautions

• TXA is absolutely contraindicated in disseminated intravascular coagulation (DIC) because inhibiting fibrinolysis in the setting of widespread clot formation can worsen the condition by preventing breakdown of pathologic clots 2, 3
• The American College of Surgeons and other guideline societies recommend that TXA should not be used in massive hematuria—preventing clot breakdown in the urinary tract can cause ureteric obstruction 3